 |
市場調查報告書
商品編碼
2126615
呼吸系統疾病治療市場：依藥物類別、應用、給藥途徑、通路及地區分類Respiratory Disease Treatment Market, By Drug Class, By Application, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
預計到 2026 年，呼吸系統疾病治療市場規模將達到 1,009.45 億美元，到 2033 年將達到 1,937.688 億美元。預計 2026 年至 2033 年的複合年成長率將達到 9.8%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 1009.45億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 9.80% | 2033年市場規模預測： | 1937.688億美元 |
氣喘、慢性阻塞性肺病（COPD）、呼吸道感染疾病、肺纖維化和其他慢性肺部疾病等呼吸系統疾病給全球醫療保健帶來了沉重負擔。全球呼吸系統疾病治療市場涵蓋多種治療方案，包括吸入劑、支氣管擴張劑、皮質類固醇、生物製藥、抗生素和其他標靶治療，旨在控制症狀、預防病情加重和改善肺功能。
全球呼吸系統疾病治療市場受到慢性呼吸系統疾病日益普遍、人口老化、空氣污染加劇以及吸入技術和專業療法進步的影響。隨著複方製劑、生物製藥、智慧吸入器和新型呼吸療法的應用日益廣泛，治療選擇也不斷增加。同時，診斷技術的進步和疾病意識的提高，使得已開發國家和新興國家的醫療保健市場都能更早、更持續地進行治療。
市場動態
全球呼吸系統疾病治療市場成長的主要促進因素是慢性呼吸道疾病（包括氣喘和慢性阻塞性肺病(COPD)）盛行率的不斷上升，以及空氣污染和香菸煙霧暴露的增加。藥物傳遞技術的進步，以及吸入療法、聯合治療和生物製藥的日益普及，正在改善疾病管理並擴大全球治療選擇。
然而，呼吸系統疾病治療市場的成長受到許多因素的限制，例如先進呼吸系統治療高成本、開發中國家缺乏專業治療資源，以及病患用藥依從性和正確使用吸入器方面存在問題。儘管如此，增加對新型生物製藥、標靶治療、新一代吸入器以及針對服務不足患者群體的呼吸系統治療的投資，將為全球呼吸系統疾病治療市場創造新的機會。
本次調查的主要特點
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數分析了全球呼吸系統疾病治療市場的主要參與者：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球呼吸系統疾病治療市場」報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用全球呼吸系統疾病治療市場分析中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管趨勢
- 產品上市及核准
- PEST分析
- 波特的分析
- 市場機遇
- 監管趨勢
- 產業趨勢
第4章 全球呼吸系統疾病治療市場：依藥物類別分類，2021-2033年
- 皮質類固醇
- 支氣管擴張劑
- 抗組織胺藥
- 白三烯受體拮抗劑
- 抗病毒藥物
- 其他
第5章 全球呼吸系統疾病治療市場：依應用領域分類，2021-2033年
- 慢性阻塞性肺病（COPD）
- 氣喘
- 急性呼吸道感染疾病
- 其他
第6章 全球呼吸道疾病治療市場：依給藥途徑分類，2021-2033年
- 口服
- 鼻腔
- 腸外
第7章 全球呼吸系統疾病治療市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第8章 全球呼吸系統疾病治療市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第9章 競爭情勢
- 公司簡介
- GSK plc
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Sanofi
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
第10章 分析師建議
- 機會分析
- 分析師意見
- Coherent Opportunity Map
第11章 參考文獻與調查方法
- 參考
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI9960
Respiratory Disease Treatment Market is estimated to be valued at USD 100,904.5 Mn in 2026 and is expected to reach USD 193,768.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 100,904.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 193,768.8 Mn |
Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), respiratory infections, pulmonary fibrosis and other chronic pulmonary disorders constitute a substantial worldwide healthcare burden. The global respiratory disease treatment market includes a range of treatment options such as inhaled medicines, bronchodilators, corticosteroids, biologics, antibiotics and other targeted treatments used for symptom control, prevention of exacerbations and improvement of lung function.
The global respiratory disease treatment market is being shaped by the increased prevalence of chronic respiratory diseases, aging populations, rising air pollution and advances in inhalation technologies and specialized therapies. The growing adoption of combination medicines, biologic treatments, smart inhalers and novel respiratory therapies continues to expand treatment options, while improved diagnosis and disease awareness support earlier and more sustained treatment in developed and emerging healthcare markets.
Market Dynamics
The global respiratory disease treatment market is driven by growing prevalence of chronic respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD), and the increasing exposure to air pollution and tobacco smoke. The rising adoption of inhaled therapies, combination treatments, and biologics, driven by advances in drug-delivery technologies, are improving disease management and increasing treatment options globally.
However, the growth of respiratory disease treatment market is limited by factors such as high cost of advanced respiratory therapies, lack of availability of specialized therapies in developing economies and issues related to patient adherence and correct inhaler use. Nevertheless, greater investment in new biologics, targeted treatments, next generation inhalers and respiratory therapies for unserved patient populations will offer opportunities in the global respiratory disease treatment market.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global respiratory disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Pfizer Inc., and Regeneron Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global respiratory disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global respiratory disease treatment market
Market Segmentation
- Drug Class Insights (Revenue, USD Mn, 2021 - 2033)
- Corticosteroids
- Bronchodilators
- Antihistamines
- Leukotriene Receptor Antagonists
- Antivirals
- Others
- Application Insights (Revenue, USD Mn, 2021 - 2033)
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Acute Respiratory Infections
- Others
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Nasal
- Parenteral
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GSK plc
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Sanofi
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Respiratory Disease Treatment Market, By Drug Class
- Global Respiratory Disease Treatment Market, By Application
- Global Respiratory Disease Treatment Market, By Route of Administration
- Global Respiratory Disease Treatment Market, By Distribution Channel
- Global Respiratory Disease Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Industry Trends
4. Global Respiratory Disease Treatment Market, By Drug Class, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Antihistamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Leukotriene Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Respiratory Disease Treatment Market, By Application, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Acute Respiratory Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Respiratory Disease Treatment Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Respiratory Disease Treatment Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Respiratory Disease Treatment Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Company Profile
- GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK plc
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
02-2729-4219
+886-2-2729-4219
消化器官系統疾病治療市場規模、佔有率和成長分析：按治療類型、適應症、給藥途徑、分銷管道和地區分類－產業預測（2026-2033 年）
急性呼吸窘迫症候群（ARDS）：全球市場展望、流行病學、競爭格局與市場預測報告（32個主要市場），2025-2035年
穿戴式慢性呼吸系統疾病設備市場規模、佔有率和成長分析：按產品類型、疾病類型、技術、最終用戶、分銷管道和地區分類－2026-2033年產業預測急性呼吸窘迫症候群（ARDS）：新療法、未滿足的需求和TPP洞察報告，2026年急性呼吸窘迫症候群（ARDS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）
急性呼吸窘迫症候群治療市場規模、佔有率、成長分析（按藥物類別、給藥途徑、分銷管道、地區分類）- 產業預測，2025 年至 2032 年